Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

Roche & Zealand Pharma join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. See why this ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

With increasing demand and higher costs, ensuring appropriate patient access is more critical than ever and 2025 will likely ...

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.

A Columbia University dermatologist argues that physicians in her specialty should be on the lookout for metabolic syndrome ...

Weight loss medications such as Wegovy and Zepbound can be effective for quick results and health benefits, but older adults ...

Fortunes are being blown on injectable hopes of a slimmer future but a simpler and cheaper alternative could actually be in ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...